Research programme: neutralising monoclonal antibodies - Amsterdam UMC/ANGANY Genetics
Latest Information Update: 01 Apr 2021
At a glance
- Originator Amsterdam UMC
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 10 Mar 2021 ANGANY Genetics and Amsterdam UMC agree to co-develop neutralizing monoclonal antibodies (NAbs) for COVID-2019 infections
- 10 Mar 2021 Preclinical trials in COVID-2019 infections (Prevention) in Netherlands (Parenteral) before March 2021
- 10 Mar 2021 Preclinical trials in COVID-2019 infections in Netherlands (Parenteral) before March 2021